Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

被引：0

作者：

Vodanovic, Ivana Dora ^{[1
]}

Nekic, Anja Barac ^{[1
]}

Sambula, Lana ^{[2
]}

Tomsic, Karin Zibar ^{[1
]}

Dusek, Tina ^{[1
,3
]}

Kastelan, Darko ^{[1
,3
]}

机构：

[1] Univ Hosp Ctr Zagreb, Dept Endocrinol, Kispaticeva 12, Zagreb 10000, Croatia

[2] Gen Hosp Tomislav Bardek, Dept Nephrol Endocrinol & Diabetol, Koprivnica, Croatia

[3] Univ Zagreb, Sch Med, Zagreb, Croatia

来源：

ENDOCRINE RESEARCH | 2025年 / 50卷 / 01期

关键词：

Adjuvant treatment; adrenal insufficiency; adrenocortical carcinoma; adverse event; hydrocortisone replacement; mitotane; EUROPEAN NETWORK; PLASMA;

D O I：

10.1080/07435800.2024.2402311

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundMitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.MethodsA retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.ResultsMitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.ConclusionCareful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.

引用

页码：50 / 56

页数：7

共 50 条

[21] Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane
Szkodziak, Piotr Robert
Czuczwar, Piotr
Wozniak, Slawomir
Szkodziak, Filip
Paszkowski, Tomasz
GINEKOLOGIA POLSKA, 2017, 88 (10) : 576 - 577
[22] Mitotane (Lysodren®) in the therapy of adrenocortical carcinoma
Raber, Wolfgang
AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2019, 12 (04): : 146 - 153
[23] Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
Basile, Vittoria
Puglisi, Soraya
Calabrese, Anna
Pia, Anna
Perotti, Paola
Berruti, Alfredo
Reimondo, Giuseppe
Terzolo, Massimo
CANCERS, 2020, 12 (09) : 1 - 15
[24] Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group Discussion
Perrier, Nancy
Scoggins, Charles
Inabnet, William ''Barry''
Gaines, Barbara
Stewart, John
Maithel, Shishir K.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2016, 222 (04) : 490 - 492
[25] First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.
Berruti, Alfredo
Fassnacht, Martin
Libe, Rossella
Lacroix, Andre
Kastelan, Darko
Haak, Harm
Arlt, Weibke
Decoudier, Benedict
Lasolle, Helene
Bancos, Irina
Quinkler, Markus
Villares Fragoso, Maria Candida Barisson
Canu, Letizia
Puglisi, Soraya
Bourdeau, Isabelle
Baudin, Eric
Berchialla, Paola
Beuschlein, Felix
Bertherat, Jerome
Terzolo, Massimo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[26] Recovery of Adrenal Insufficiency is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
Poirier, Jonathan
Gagnon, Nadia
Terzolo, Massimo
Puglisi, Soraya
El Ghorayeb, Nada
Calabrese, Anna
Lacroix, Andre
Bourdeau, Isabelle
CANCERS, 2020, 12 (03)
[27] Is there a role for low doses of mitotane (o,p′-DDD) as adjuvant therapy in adrenocortical carcinoma?
Dickstein, G
Shechner, C
Arad, E
Best, LA
Nativ, O
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09): : 3100 - 3103
[28] Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma
Berruti, A
Terzolo, M
Pia, A
Angeli, A
Dogliotti, L
CANCER, 1998, 83 (10) : 2194 - 2200
[29] Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report
Baszko-Blaszyk, Daria
Ochmanska, Katarzyna
Wasko, Ryszard
Sowniski, Jerzy
ENDOKRYNOLOGIA POLSKA, 2011, 62 (02) : 186 - 188
[30] Commentary: Adjuvant Mitotane for adrenocortical cancer - A recurring controversy
Huang, Hui
Fojo, Tito
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (10): : 3730 - 3732

← 1 2 3 4 5 →